ERBB2 and neoplasm: HER2-targeted therapeutic drugs (such as trastuzumab) significantly inhibit tumor cell proliferation and metastasis by blocking HER2 dimerization and inhibiting signaling pathways such as PI3K/AKT and MAPK (102).